SEC Form 6-K filed by Takeda Pharmaceutical Company Limited
$TAK
Biotechnology: Pharmaceutical Preparations
Health Care
FORM 6-K
U.S. SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For the month of June 2025
Commission File Number: 001-38757
TAKEDA PHARMACEUTICAL COMPANY LIMITED
(Translation of registrant’s name into English)
1-1, Nihonbashi-Honcho 2-Chome
Chuo-ku, Tokyo 103-8668
Japan
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Information furnished on this form:
EXHIBIT
Exhibit Number | ||||||||
| 1 | ||||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| TAKEDA PHARMACEUTICAL COMPANY LIMITED | |||||||||||
| Date: June 12, 2025 | By: | /s/ Norimasa Takeda | |||||||||
Norimasa Takeda Chief Accounting Officer and Corporate Controller | |||||||||||
| [Cover] | |||||
| [Document Filed] | Share Repurchase Report | ||||
| [Applicable Law] | Article 24-6, paragraph 1 of the Financial Instruments and Exchange Act of Japan | ||||
| [Filed with] | Director, Kanto Local Finance Bureau | ||||
| [Filing Date] | June 12, 2025 | ||||
| [Reporting period] | From May 1, 2025 to May 31, 2025 | ||||
| [Company Name] | Takeda Pharmaceutical Company Limited | ||||
| [Title and Name of Representative] | Christophe Weber, Representative Director, President & Chief Executive Officer | ||||
| [Address of Head Office] | 1-1, Doshomachi 4-chome, Chuo-ku, Osaka | ||||
| (The above address is the registered head office location and the ordinary business operations are conducted at the “Nearest Place of Contact”) | |||||
| [Telephone Number] | Not applicable | ||||
| [Name of Contact Person] | Not applicable | ||||
| [Nearest Place of Contact] | 1-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo | ||||
| (Global Headquarters) | |||||
| [Telephone Number] | +81-3-3278-2111 (Main telephone number) | ||||
| [Name of Contact Person] | Norimasa Takeda, Chief Accounting Officer & Corporate Controller, Global Finance | ||||
| [Place for public inspection] | Takeda Pharmaceutical Company Limited (Global Headquarters) | ||||
| (1-1, Nihonbashi Honcho 2-chome, Chuo-ku, Tokyo) | |||||
| Tokyo Stock Exchange, Inc. | |||||
| (2-1, Nihonbashi Kabutocho, Chuo-ku, Tokyo) | |||||
| Nagoya Stock Exchange, Inc. | |||||
| (8-20, Sakae 3-chome, Naka-ku, Nagoya) | |||||
| Fukuoka Stock Exchange | |||||
| (14-2, Tenjin 2-chome, Chuo-ku, Fukuoka) | |||||
| Sapporo Security Exchange | |||||
| (14-1, Minamiichijonishi 5-chome, Chuo-ku, Sapporo) | |||||
Class of Shares: Common Stock
1.Status of repurchase
(1)Status of repurchase pursuant to a resolution approved by a General Meeting of Shareholders
Not applicable
Not applicable
(2)Status of repurchase pursuant to a resolution approved by a meeting of the Board of Directors
| As of May 31, 2025 | |||||||||||
Number of shares (shares) | Total repurchase amount (JPY) | ||||||||||
Status of the resolution of the Board of Directors (January 30, 2025) (Period of repurchase: from February 17, 2025 to May 31, 2025) | 28,500,000 | 100,000,000,000 | |||||||||
Repurchases during this reporting month (Date of repurchase) | (Date) | ||||||||||
| — | — | — | |||||||||
Total | — | — | — | ||||||||
Aggregate shares repurchased as of the end of this reporting month | 23,367,100 | 99,955,865,500 | |||||||||
Progress of share repurchase (%) | 81.99 | 99.96 | |||||||||
(Notes) 1. The period of repurchase is based on a trade date, while the date of repurchase is based on the settlement date.
2. It was resolved at the above meeting of the Board of Directors that the method of acquisition shall be open-market repurchase through a trust bank.
3. The acquisition of shares based on the above resolution of the Board of Directors was completed on April 23, 2025 (settlement date basis).
2.Status of disposition
Not applicable
3.Status of treasury shares held
| As of May 31, 2025 | |||||
Status of treasury shares held as of the end of the reporting month | Number of shares (shares) | ||||
Total number of issued shares | 1,590,961,709 | ||||
Number of treasury shares held | 23,558,168 | ||||
(Notes) 1. The number of treasury shares held includes shares purchased on a demand for purchase made by shareholders holding shares less than one unit.
2. The number of treasury shares held does not include the shares held by the ESOP trust account and the shares held by the BIP trust account.